方法：回顾性队列研究。收集2015-03/2019-08于我院确诊为高度近视继发CNV的患者46例46眼，根据玻璃体腔注射康柏西普或雷珠单抗治疗分为康柏西普组20例20眼，雷珠单抗组26例26眼。比较两组患者治疗前，治疗后1、3、6mo的最佳矫正视力(BCVA)、光学相干断层扫描(OCT)测量的黄斑中心凹视网膜厚度(CMT)、注药次数及并发症情况。

结果：治疗前康柏西普组和雷珠单抗组患者BCVA(LogMAR)分别为0.81±0.51、0.83±0.66(P=0.900)，治疗后1、3、6mo康柏西普组患者BCVA(LogMAR)为0.59±0.33、0.49±0.34、0.44±0.32，雷珠单抗组为0.53±0.54、0.47±0.47、0.40±0.43，两组治疗后各时间点BCVA均较治疗前有改善(均P<0.001)。治疗前康柏西普组和雷珠单抗组患者CMT分别为242.30±73.27、233.38±66.63μm(P=0.669)，治疗后1、3、6mo康柏西普组患者CMT为217.00±54.78、208.65±55.38、206.00±45.34μm，雷珠单抗组为197.42±50.47、198.38±55.19、192.15±51.97μm，两组治疗后各时间点CMT较治疗前均有下降(均P<0.05)。治疗后1、3、6mo两组间BCVA、CMT和治疗6mo内注药次数比较均无差异(均P>0.05)。治疗期间所有患者未发生全身不良反应及眼部严重并发症。

结论：玻璃体腔注射康柏西普和雷珠单抗治疗高度近视继发CNV，能提高患眼BCVA、降低CMT，疗效相似，均可作为高度近视继发CNV的治疗选择。

METHODS: A retrospective cohort study. This study included 46 patients(46 eyes)with myopic CNV who were treated with conbercept(conbercept group, 20 cases, 20 eyes)or ranibizumab(ranibizumab group, 26 cases, 26 eyes)from March 2015 to August 2019. Central macular thickness(CMT), the number of injections and complications measured by best-corrected visual acuity(BCVA)and optical coherence tomography(OCT)were compared between the two groups before treatment and 1, 3, 6mo after treatment.

RESULTS: Before treatment, the BCVA(LogMAR)of conbercept and ranibizumab groups were 0.81±0.51, 0.83±0.66(P=0.900). After treatment, the BCVA(LogMAR)in the conbercept group at 1, 3 and 6mo were 0.59±0.33, 0.49±0.34, 0.44±0.32, in the ranibizumab group were 0.53±0.54, 0.47±0.47, 0.40±0.43. The BCVA was significantly improved in both groups after treatment(all P<0.001). Before treatment, the CMT of conbercept and ranibizumab groups were 242.30±73.27, 233.38±66.63μm(P=0.669). After treatment, the CMT in the conbercept group at 1, 3, and 6mo were 217.00±54.78, 208.65±55.38, 206.00±45.34μm, in the ranibizumab group were 197.42±50.47, 198.38±55.19, 192.15±51.97μm. The CMT was significantly decreased in both groups after treatment(all P<0.05). There were no significant differences in the number of injections, BCVA and CMT at each follow-up time points between conbercept and ranibizumab groups(all P>0.05). Systemic adverse reactions and serious ocular complications were not found during the treatment period.

CONCLUSION: Intravitreal conbercept or ranibizumab provide similar efficacy to improve the BCVA and reduce the CMT in the patients with myopic CNV. Both conbercept and ranibizumab could be a choice of treatment for myopic CNV.